56850-93-2

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 4-(2-aminoethoxy)benzoate is used as a local anesthetic for minor skin irritations, sunburns, and insect bites. It is incorporated into over-the-counter topical treatments due to its ability to numb the area where it is applied.
Used in Cosmetic Industry:
Methyl 4-(2-aminoethoxy)benzoate is used as a pain-relieving agent in cosmetic products, such as lip balms and other skincare formulations, to provide temporary relief from discomfort and irritation.
Used in Dental Industry:
Methyl 4-(2-aminoethoxy)benzoate is used as a local anesthetic in dental procedures to numb the gums and surrounding tissues, providing patients with a more comfortable experience during dental treatments.

Upstream product

• 151-56-4 ethyleneimine 
• 99-76-3 methyl 4-hydroxylbenzoate 
• 56850-91-0 methyl 4-(2-bromoethoxy)benzoate 
• 26690-80-2 2-(N-tert-butoxycarbonylamino)ethanol 
• 174666-16-1 4-(2-tert-butoxycarbonylaminoethoxy)benzoic acid methyl ester 
• 137988-24-0 methyl 4-(cyanomethoxy)benzoate 
• 113459-58-8 N-[2-(4-Methoxycarbonylphenoxy)ethyl]phthalimide 

Downstream Products

• 142783-58-2 4-{2-[3-(6-Chloro-pyridazin-3-yloxy)-2-hydroxy-propylamino]-ethoxy}-benzoic acid methyl ester 
• 1012058-32-0 (Z)-methyl 4-(2-(5-((5-fluoro-2-oxo-indolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamido)ethoxy)benzoate 
• 1178873-64-7 methyl 4-[2-({4-chloro-2-[(diphenylmethyl)amino]benzoyl}amino)ethoxy]benzoate 
• 1178873-87-4 methyl 4-[2-({[2-(benzylamino)phenyl]carbonyl}amino)ethoxy]benzoate 
• 783356-68-3 abexinostat 
• 866599-49-7 trans 4-[2-(3-benzofuran-2-ylbut-2-enoyl-amino)ethoxy]benzoic acid methyl ester 
• 174665-29-3 3-{4-[2-(pyrimidin-2-ylamino)ethyloxy]benzoylamino}-2(S)-benzenesulfonylaminopropionic acid tert-butyl ester 
• 174665-30-6 3-{4-[2-(pyrimidin-2-ylamino)ethyloxy]benzoylamino}-2(S)-benzenesulfonylaminopropionic acid 
• 174665-28-2 4-[2-(pyrimidin-2-ylamino)ethyloxy]benzoic acid 
• 174665-27-1 methyl 4-[2-(pyrimidin-2-ylamino)ethyloxy]benzoate 

Relevant academic research and scientific papers

Novel PHD2/HDACs hybrid inhibitors protect against cisplatin-induced acute kidney injury

Acute kidney injury (AKI) is associated with high morbidity and mortality. Cisplatin is a common chemotherapeutic, but its nephrotoxicity-driven AKI limits its clinical application. Currently, there are no specific and satisfactory therapies in the clinic for AKI. Inhibitors of hypoxia-inducible factor prolyl hydroxylase 2 (HIF-PHD2) or histone deacetylase (HDACs) had shown renoprotective effects against AKI in preclinical studies. This study aimed to develop a novel therapeutic to prevent AKI progression by targeting PHD2 and HDACs simultaneously. We designed and synthesized a series of PHD2/HDACs hybrid inhibitors. The initial drug activity screening identified a candidate compound 31c, which exhibited potent inhibitory activities against PHD2 and HDAC1/2/6. Cellular analyses further showed that 31c did not affect cisplatin's antitumor activity in cancer cells but strongly protected cisplatin-induced toxicity on HK-2 cells. In vivo studies with the cisplatin-induced AKI mouse model demonstrated that 31c remarkably alleviated kidney dysfunction with suppressed plasma BUN/SCr and increased EPO levels. The potent renoprotective effects of 31c on AKI were confirmed by significant improvements in pathological kidney conditions in the mouse model. These results suggest that the novel PHD2/HDACs hybrid inhibitor, 31c, has a clinical potential as the renoprotective agent for the treatment/prevention of cisplatin-induced AKI for various cancers.

A method for preparing ilastatin is disclosed. Preparation method of intermediate and intermediate

The preparation method comprises the following steps: (1) the first intermediate 3 - (dimethylamino) methyl) benzofuran -2 - carboxylic acid and second intermediate 4 - (2 - aminoethoxy) methyl benzoate are subjected to amide condensation to obtain third

Dual inhibitor for prolyl hydroxylase and histone deacetylase, preparation method and application thereof

The invention discloses a new dual inhibitor for prolyl hydroxylase and histone deacetylase shown as formula I, a preparation method and an application thereof. The new dual inhibitor is capable of selectively promoting the level of hypoxia-inducible fact

Sustainable poly(ether amide)s from lignin-derived precursors

In recent years, there have been concerted efforts to replace petrochemical products with those from renewable sources due to the unsustainability of petroleum feedstock, and the continued volatility in the price. This work describes the synthesis and thermal properties of two new lignin-derived poly(ether-amide)s as alternative thermoplastics to petroleum-based commodities. Poly-4-(2-aminoethoxy)benzoate (PEAB) and poly-4-(2-aminoethoxy)-3-methoxybenzoate (PEAV) are synthesized by a melt polycondensation and characterized by 1H NMR spectroscopy and thermal analysis. The number average molecular weight (Mn) of the polymers are estimated from the 1H NMR spectroscopy analysis, and were shown to be 4100 and 12,000 g/mol for PEAB and PEAV respectively. The PEAB had a higher decomposition temperature (Td) as well as glass transition temperature (Tg) compared to PEAV; albeit, with a lower molecular weight. The polymers’ Td were in the range of 330 °C–380 °C and the Tg were between 100 °C and 120 °C. The thermal properties of the polymers are in the desirable range for thermoplastic materials used in the packaging, storage, and coating industries. Furthermore, the polymers are susceptible to degradation under acidic conditions in a short period; a property that is highly desirable for degradable polymers.

SUBSTITUTED 2-INDOLINONE AS PTK INHIBITORS CONTAINING A ZINC BINDING MOIETY

The present invention relates to substituted 2-indolinone containing zinc- binding moiety based derivatives that have enhanced or unique properties as inhibitors of protein tyrosine kinase (PTK) receptors and their use in the treatment of PTK related diseases and disorders such as cancer. The said derivatives may further act as HDAC inhibitors.

MULTI-FUNCTIONAL SMALL MOLECULES AS ANTI-PROLIFERATIVE AGENTS

The present invention relates to the compositions, methods, and applications of a novel approach to selective inhibition of several cellular or molecular targets with a single small molecule. More specifically, the present invention relates to multi-functional small molecules wherein one functionality is capable of inhibiting histone deacetylases (HDAC) and the other functionality is capable of inhibiting a different cellular or molecular pathway involved in aberrant cell proliferation, differentiation or survival.

Nonpeptide α(v)β3 antagonists. 1. Transformation of a potent, integrin-selective α(IIb)β3 antagonist into a potent α(v)β3 antagonist

Modification of the potent fibrinogen receptor (α(IIb)β3) antagonist 1 generated compounds with high affinity for the vitronectin receptor α(v)β3. Sequential modification of the basic N-terminus of 1 led to the identification of the

β-adrenergic agonists

β-adrenergic agonists for the treatment of diseases/conditions such as obesity and diabetes. The compounds have formula (I), wherein R1, R2, R3, R4, R5, R6, R7, W, X, Y and Z are as defined in the specification.

Synthesis and activities of new arylsulfonamido thromboxane A2 receptor antagonists

New benzoic, benzeneacetic and thiazole-4-acetic acids bearing an arylsulfonamido alkyl or alkylhetero side chain were synthesized and tested in vitro for affinity for human platelet thromboxane A2 receptors and inhibition of U46619-induced rat aortic ring contraction.Influence of substitution patterns, chain length and presence of heteroatoms were studied and compounds within a 30 nmol range for inhibition of U46619-induced contractions were found.One of the most potent, 2-thiazole-4-acetic acid (VII-4) was orally active (1 mg/kg), as evidenced by the inhibition of U46619-induced platelet aggregation in guinea pigs, ex vivo. thromboxane A2 / receptor antagonist / platelet aggregation / arylsulfonamido derivative